EUCTR2015-002921-20-GB进行中（未招募）1 期
A Phase 3 Open-Label Extension Study to Evaluate the Long-Term Safety of Omiganan Topical Gel in Subjects with Rosacea
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 300
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1. Subjects who have provided written informed consent to participate in the study.
- •2. Healthy, male and nonpregnant female subjects, 18 years of age or older.
- •3. A diagnosis of severe papulopustular rosacea using the Investigator Global Assessment (IGA) grading scale (Grade 4; described as numerous (=20) small and or large inflammatory papules/ pustules, and up to 2 nodules, (at baseline))
- •4. Subjects with the presence of telangiectasia at Baseline
- •5. Subjects with the presence of facial erythema associated with their rosacea at Baseline
- •6. Non-nursing, female subjects of child bearing potential, who are using a highly effective form of birth control or females not of childbearing potential due to menopause (must be postmenopausal for at least one year).
- •Highly effective methods of birth control are defined as those, alone or in combination, that result in a low failure rate (i.e. less than 1% per year) when used consistently and correctly. Forms of birth control include: Oral (birth control pills), Intravaginal: (e.g. NuvaRing®), Implantable (e.g. Norplant®), injectable (e.g. Depo-Provera®) or transdermal (e.g Ortho Evra®) contraception; intrauterine device (IUD); double-barrier (diaphragm or condom with spermicidal gel or foam); for two months prior to study enrollment or a vasectomized partner or true abstinence (in line with preferred and usual lifestyle of subject) with an acceptable form of birth control should the subject become sexually active. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception. All female subjects of child bearing potential must undergo an in-office, highly sensitive urine pregnancy test, with a negative result, prior to receiving study drug. In addition, women of childbearing potential must agree to have a highly sensitive urine pregnancy test at the end of the study.
- •7. Subjects who are willing and able to return to the study clinic for the designated study visits.
- •8. Subjects who are willing to refrain from sunbathing, using sun tanning booths/beds, or excessive exposure to the sun for the duration of the study.
- •9. Subjects who are willing to comply with the protocol and visit requirements.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 250
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 50
排除标准
- •1. Subjects with clinically significant abnormal findings at the Screening or Baseline/Day 1 Visit that would require a new intervention or treatment or a change in treatment that would in the opinion of the investigator supersede participation in the clinical trial.
- •2. Subjects with steroid rosacea or subtype 3 (phymatous rosacea).
- •3. Subjects with nodular rosacea (defined as more than 2 lesions greater than 5 mm).
- •4. Subjects with underlying diseases or other dermatological conditions, such as; atopic dermatitis, perioral dermatitis, or seborrheic dermatitis, which requires the use of interfering topical or systemic therapy or may interfere with the rosacea diagnosis or its assessment.
- •5. Subjects with known allergies to the active ingredient or any of the excipients. (See Section 7.5.2)
- •6. Subjects who have not undergone the specified washout period(s) for the following topical preparations applied to the face or subjects who require the concomitant use of any of the following topical preparations/treatments applied to the face:
- •Product Washout Period
- •(Prior to Baseline/First Dose)
- •? Abradants, astringents, toners, facials, masks, or moisturizers
- •containing retinols, AHA (alpha hydroxyl acids),
- •salicylic acids 1 week
- •? Tanning booths/beds 2 weeks
- •? Antibiotics (other than topical ocular application) 2 weeks
- •? Antimicrobial soaps 2 weeks
- •? Corticosteroids 2 weeks
- •? Other anti-inflammatories 2 weeks
- •? Other rosacea treatments (e.g., azelaic acid,
- •metronidazole, ivermectin, sulfacetamide) 2 weeks
- •? Retinoids 4 weeks
- •7. Subjects who have not undergone the specified washout period(s) for the following systemic treatments or subjects who require the concomitant use of any of the following systemic treatments:
- •Product Washout Period
- •(Prior to Baseline/First Dose)
- •? Antibiotics 4 weeks
- •? Corticosteroids 4 weeks
- •? Retinoids 4 weeks
- •8. Female subjects who are pregnant, nursing, or planning a pregnancy within the study period.
- •9. Subjects using an investigational drug within 30 days of the Baseline Visit or who are currently participating in an investigational study. Use of an investigational drug/device and/or participation in another investigational study is prohibited during this study.
- •10. Subjects who currently abuse alcohol or drugs or who have a history of chronic alcohol or drug abuse with in the past year.
- •11. Subjects who have a chronic medical condition that may require the use of a prohibited medication to treat new symptoms or exacerbations, for example, rheumatoid arthritis.
研究者
相似试验
尚未招募
3 期
A Phase 3 Open-Label Extension Study to Evaluate the Long-Term Safety of Omiganan Topical Gel in Subjects with Rosacea10014982acne rosaceaNL-OMON42492Cutanea Life Sciences26
进行中（未招募）
1 期
A Phase 3 Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Vibegron in Men with Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH) - Vibegron in Men with OAB for BPHOveractive Bladder (OAB) in men with Benign Prostatic Hyperplasia (BPH)MedDRA version: 23.1Level: LLTClassification code 10059617Term: Overactive bladderSystem Organ Class: 10038359 - Renal and urinary disordersEUCTR2018-003136-72-PLrovant Sciences GmbH300
进行中（未招募）
1 期
A Phase 3 Open-Label Extension Study to Evaluate the Long-Term Safety of Omiganan Topical Gel in Subjects with RosaceaPapulopustular RosaceaMedDRA version: 18.1Level: PTClassification code 10039218Term: RosaceaSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2015-002921-20-SECutanea Life Sciences, Inc.300
进行中（未招募）
1 期
A Phase 3 Open-Label Extension Study to Evaluate the Long-Term Safety of Omiganan Topical Gel in Subjects with RosaceaEUCTR2015-002921-20-NLCutanea Life Sciences, Inc.300
进行中（未招募）
不适用
A Phase III Open-Label Extension Study to Assess the Safety and Efficacy of Tobramycin Inhalation Powder after Manufacturing Process Modifications (TIPnew) in Cystic Fibrosis (CF) Subjects Who Completed Participation in Study CTBM100C2303.Pseudomonas aeruginosa infection in cystic fibrosis patientsMedDRA version: 13.1Level: LLTClassification code 10021860Term: Infection pseudomonas aeruginosaSystem Organ Class: 10021881 - Infections and infestationsEUCTR2008-004764-39-LTovartis Pharma Services AG100